Silicone PSA Patents: Leaders, Filing Trends & White Space 2026
- 57.7% concentration. The five leading assignees together hold 1,703 of the 2,949 records in scope — the field is not fragmented at the top.
- Filings down 68% since the 2021 peak window. From 136 filings in 2021 to 43 in 2024, the last year the data can be treated as complete.
- Adhesives claims dominate, medical use is a strong secondary axis. C09J covers 57.4% of records, while A61K and A61F together point to a substantial wound-care and transdermal cluster.
Filing growth compares 2021 (136 records) with 2024 (43) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,949 records in scope (CR5), not by the ranked leaders only.
What this dataset covers
Silicone pressure sensitive adhesives sit at the intersection of polymer chemistry and medical device engineering. The search underlying this page pulls 2,949 published records filed or published between 2015 and mid-2026, built around core terms like MQ resin, platinum cure, and peel adhesion combined with silicone PSA and silicone adhesive tape language. That combination captures both the classic industrial masking and release-liner applications and the medical-grade skin-contact adhesive segment that has grown around transdermal drug delivery and wound closure.
Because the search terms bridge chemistry and device claims, the record set spans multiple IPC subclasses at once — a single filing on a wound dressing adhesive can carry adhesives, medicinal preparation, and implant classifications simultaneously. That overlap is deliberate: it reflects how the underlying technology is actually claimed, not a quirk of the search.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
How the field has moved and where it sits in the classification system
Two views matter here: the year-by-year filing count, which shows momentum, and the IPC subclass breakdown, which shows what kind of claims dominate the corpus.
A pulled-back filing curve after 2019
Filings ran from 130 in 2017 to a peak of 152 in 2019, then eased through the early 2020s to 136 in 2021 and 43 in 2024 — a 68% decline over that three-year span. 2025 and 2026 figures are still incomplete because publication lags filing by roughly 18 months, so the true recent-year count is understated and should not yet be read as a continued fall.
Adhesives claims lead, medical-use classes form a secondary cluster
C09J (Adhesives) appears on 57.4% of the 2,949 records, far ahead of any other class. C08L (Polymer compositions) and B32B (Layered products) each sit near 16%, while A61K (Medicinal preparations) and A61F (Implants & prostheses) together mark a meaningful medical-device sub-corpus layered on top of the core adhesive chemistry.
Shares are the percentage of the 2,949 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Silicone Pressure Sensitive Adhesives with Eureka
This page is one run against one query. Ask Eureka your own question about silicone pressure sensitive adhesives and every answer comes back with the patent numbers behind it.
Try EurekaA recent filing that shows where the claim language is heading
Silicone Based Pressure Sensitive Adhesive Tapes — US20250326954A1
Silicone pressure sensitive adhesives are described which exhibit unique properties enabling their use in various medical, microbiology, and life science applications. Also described are various silicone adhesive tape constructions which include one or more regions of the silicone-based pressure sensitive adhesives. In addition, systems and methods of using the silicone adhesives and silicone adhesive tapes are described, such as evaluating biological samples using the silicone adhesive tapes.Filed by Avery Dennison, this application extends silicone PSA tape constructions into microbiology and life-science sample handling — a use case adjacent to, but distinct from, the transdermal drug delivery and wound-closure claims that dominate the most-cited older records.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5023252A | Transdermal and trans-membrane delivery of drugs | 2,799 |
| 2 | US4728571A | Polysiloxane-grafted copolymer release coating sheets and adhesive tapes | 967 |
| 3 | US20050182443A1 | Adhesive-containing wound closure device and method | 958 |
| 4 | US5804610A | Methods of making packaged viscoelastic compositions | 823 |
| 5 | US6569521B1 | Stretch releasing pressure sensitive adhesive tape and articles | 604 |
| 6 | US5082706A | Pressure sensitive adhesive/release liner laminate | 573 |
| 7 | US5248739A | Silicone pressure sensitive adhesives having enhanced adhesion to low energy substrates | 536 |
| 8 | US5531855A | Carrier delivered dressing and method of manufacture | 487 |
| 9 | US5738642A | Carrier delivered dressing and method of manufacture | 422 |
| 10 | US5270358A | Composite of a disperesed gel in an adhesive matrix | 384 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this searched corpus — read them as a signal of influence on later filers, not as a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about the state of the field
Three patterns stand out once the filing trend, concentration figures, and classification shares are read together.
The top of the field is settled
Five assignees together account for 1,703 of the 2,949 records in scope, and the top ten reach 72.6%. New entrants are filing against an already-dense claim base rather than into open territory.
A cooling filing curve, not a collapse
Filings fell from 136 in 2021 to 43 in 2024, the last year that can be treated as complete. The peak was 2019 at 152, meaning the field has been retreating from its high-water mark for several years even before the most recent, still-incomplete years are counted.
Medical use is a real secondary axis, not noise
Alongside the 57.4% core adhesives share, A61K and A61F classes each cover a meaningful slice of records — evidence that transdermal and wound-care applications are claimed as a distinct branch rather than folded into general adhesive chemistry.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to silicone pressure sensitive adhesives, with the prior art for and against each one.
Who holds the claim space, and where activity has slowed
The ranking covers 100 companies counted by record volume. It is not a top-50 or top-100 list in the conventional sense — it is the full set the data endpoint returns — but the shape of it is unambiguous: a small group holds most of the field, and recent-year filing has slowed even for that group.
A single assignee well ahead of the field
The leading assignee holds 778 records, more than five times the count at fifth place (133). That gap is the clearest sign that the field's core claim positions were established early and defended since.
Even top filers have gone quiet recently
Several of the most active historical assignees show zero filings in the latest year, with year-over-year drops as steep as -100% for some and -75% for others. This tracks the broader 2021-to-2024 decline rather than signalling any single company's retreat.
Filing partnerships are narrow and concentrated
Only 10 co-assignee pairs appear in the dataset, and the strongest pairings sit within a small cluster tied to transdermal drug delivery partnerships rather than being spread across the field.
| Assignee | Recent year | YoY |
|---|---|---|
| Momentive Performance Materials Inc | 2 | -33% |
| 3M Innovative Properties Co | 1 | -75% |
| Dow Silicones Corp | 0 | -100% |
| 3M Company | 0 | — |
| General Electric Co | 0 | — |
| Avery Dennison Corp | 0 | -100% |
| Noven Pharmaceuticals Inc | 0 | — |
| LTS Lohmann Therapie-Systeme AG | 0 | — |
Where to take this from here
The landscape view answers who and how much. The questions that follow are about specific claims and specific white space.
Check freedom to operate against the leader's portfolio
With 778 records held by a single assignee, any new filing in core silicone PSA chemistry should be checked against that portfolio specifically before drafting claims.
Explore assignee claims in EurekaMap the under-claimed branches in detail
The gate chips above point to sub-areas with thinner density. Confirming that with claim-level search, not just IPC share, is the next step before committing R&D spend.
Run a white space search in EurekaCommon questions on silicone PSA patents
The dataset shows one assignee well ahead of the rest, holding 778 of the 2,949 records in scope, with the fifth-place company at 133. This gap is large enough that any new entrant should assume the leading player's portfolio covers much of the core platinum-cure and MQ resin chemistry before drafting new claims. The next four companies bring the top-5 combined share to 57.7% of all records, so the concentration extends beyond just the single leader.
Filings peaked in 2019 at 152 and had fallen to 43 by 2024, a 68% decline from the 2021 level of 136. That 2024 figure is the most recent year that can be treated as reasonably complete, because publication typically lags filing by around 18 months. The apparent drop in 2025 and 2026 in raw counts should not be read as a further decline — those years are still filling in.
C09J covers adhesives directly and applies to 57.4% of the 2,949 records, making it the dominant classification in this corpus. C08L covers polymer compositions more broadly and applies to 16.3% of records — it captures the underlying silicone polymer chemistry rather than the adhesive application itself. A single filing often carries both classes, since a silicone PSA patent typically claims both the polymer formulation and its use as an adhesive.
Relative to the dense core of adhesive and medicinal-preparation claims, sub-areas like high-temperature masking tape constructions, coat-weight control in silicone transfer adhesives, and MQ resin ratio optimisation for peel adhesion show thinner coverage. That does not guarantee freedom to operate, but it does indicate fewer competing claims to design around. A claim-level search within Eureka against the specific formulation variables is the recommended next step before relying on this signal alone.
The search terms used to build this dataset include peel adhesion and platinum cure language that appears heavily in transdermal drug delivery and wound closure patents, which is why A61K (Medicinal preparations, 15.7% of records) and A61F (Implants & prostheses, 8.1%) show up as significant secondary classes. This reflects a genuine sub-corpus of medical-grade silicone adhesive filings, not classification noise. Companies filing in this space, such as those behind transdermal patch technology, tend to claim both the adhesive chemistry and its medical application in the same family.
Research Silicone Pressure Sensitive Adhesives in depth with Eureka
Go past this page: query the whole silicone pressure sensitive adhesives corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.